The FDA’s real-time clinical trial mechanism allows drug sponsors to transmit data immediately to the regulator through the ...
Morning Overview on MSN
FDA pilots AI and real-time data reviews to speed some clinical trials
A cancer patient enrolled in a clinical trial today might wait months before regulators ever see the safety data generated by ...
Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...
Overall survival with serplulimab, a novel PD-1 inhibitor being developed in China for extensive-stage small cell lung cancer (ES-SCLC), appears better than that seen with two immune checkpoint ...
WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial presented at the ...
Credit: Amgen. The application is supported by data from the phase 2 DeLLphi-301 trial. Results showed 40% of patients responded to treatment with Imdelltra. The Food and Drug Administration (FDA) has ...
Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to ...
Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...
Despite advances in immunotherapy and evolving treatment guidelines, many patients never make it to later lines of therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results